Genmab Management

Management criteria checks 4/4

Genmab's CEO is Jan van de Winkel, appointed in Jun 2010, has a tenure of 12.08 years. total yearly compensation is DKK38.10M, comprised of 20.7% salary and 79.3% bonuses, including company stock and options. directly owns 0.94% of the company’s shares, worth €214.42M. The average tenure of the management team and the board of directors is 3.3 years and 5.3 years respectively.

Key information

Jan van de Winkel

Chief executive officer

kr.38.1m

Total compensation

CEO salary percentage	20.7%
CEO tenure	12.1yrs
CEO ownership	0.9%
Management average tenure	3.3yrs
Board average tenure	5.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jan van de Winkel's remuneration changed compared to Genmab's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2022	n/a	n/a	kr.2b
Dec 31 2021	kr.38m	kr.8m	kr.3b
Sep 30 2021	n/a	n/a	kr.3b
Jun 30 2021	n/a	n/a	kr.3b
Mar 31 2021	n/a	n/a	kr.6b
Dec 31 2020	kr.37m	kr.7m	kr.5b
Sep 30 2020	n/a	n/a	kr.6b
Jun 30 2020	n/a	n/a	kr.6b
Mar 31 2020	n/a	n/a	kr.2b
Dec 31 2019	kr.35m	kr.7m	kr.2b
Sep 30 2019	n/a	n/a	kr.2b
Jun 30 2019	n/a	n/a	kr.1b
Mar 31 2019	n/a	n/a	kr.1b
Dec 31 2018	kr.28m	kr.7m	kr.1b
Sep 30 2018	n/a	n/a	kr.1b
Jun 30 2018	n/a	n/a	kr.1b
Mar 31 2018	n/a	n/a	kr.1b
Dec 31 2017	kr.27m	kr.7m	kr.1b
Sep 30 2017	n/a	n/a	kr.1b
Jun 30 2017	n/a	n/a	kr.1b
Mar 31 2017	n/a	n/a	kr.1b
Dec 31 2016	kr.23m	kr.6m	kr.1b
Sep 30 2016	n/a	n/a	kr.735m
Jun 30 2016	n/a	n/a	kr.686m
Mar 31 2016	n/a	n/a	kr.535m
Dec 31 2015	kr.20m	kr.5m	kr.764m

Compensation vs Market: Jan's total compensation ($USD5.18M) is about average for companies of similar size in the German market ($USD4.53M).

Compensation vs Earnings: Jan's compensation has been consistent with company performance over the past year.

CEO

Jan van de Winkel (61 yo)

12.1yrs

Tenure

kr.38,100,000

Compensation

Dr. Jan G. J. van de Winkel, Ph D., serves as a Member of Advisory board at Thuja Capital Management B.V. Dr. van de Winkel served as a Member of Scientific Advisory Board.He is a Co-Founder of Genmab A/S...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jan van de Winkel	Co-Founder	12.1yrs	kr.38.10m	0.94% DKK 214.4m
Anthony Pagano	Executive VP & CFO	2.3yrs	kr.12.40m	0.0047% DKK 1.1m
Anthony Mancini	Executive VP & COO	2.3yrs	kr.16.60m	no data
Judith Klimovsky	Executive VP & Chief Development Officer	5.4yrs	kr.19.80m	0.0080% DKK 1.8m
Tahamtan Ahmadi	Executive VP	1.3yrs	kr.10.90m	0.0037% DKK 841.4k
Mijke Zachariasse	Director of Protein Production & Chemist and Non-Independent Director	no data	kr.900.00k	0.00014% DKK 31.9k
Rima Nassar	VP, Head of Global Regulatory Affairs – Oncology & Non-Independent Director	no data	kr.800.00k	0.0016% DKK 362.6k
Peter Ros	Senior Director of Finance & Accounting	no data	no data	no data
Andrew Carlsen	Senior Director	no data	no data	no data
Birgitte Stephensen	Executive VP & Chief Legal Officer	12.5yrs	no data	no data
Christopher Cozic	Executive VP & Chief People Officer	no data	no data	no data
Rachel Gravesen	Executive Officer	3.3yrs	no data	no data

3.3yrs

Average Tenure

52.5yo

Average Age

Experienced Management: GE9's management team is considered experienced (3.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Mijke Zachariasse	Director of Protein Production & Chemist and Non-Independent Director	3.3yrs	kr.900.00k	0.00014% DKK 31.9k
Rima Nassar	VP, Head of Global Regulatory Affairs – Oncology & Non-Independent Director	2.5yrs	kr.800.00k	0.0016% DKK 362.6k
Anders Pedersen	Non-Independent Director	18.7yrs	kr.1.40m	0.017% DKK 3.9m
Deirdre Connelly	Independent Chairman of the Board	5.3yrs	kr.2.40m	0.0068% DKK 1.6m
Rolf Hoffmann	Independent Director	5.3yrs	kr.1.40m	0.0045% DKK 1.0m
Pernille Erenbjerg	Independent Deputy Chairman	7.5yrs	kr.1.80m	0.0066% DKK 1.5m
Paolo Paoletti	Independent Director	7.5yrs	kr.1.30m	0.00093% DKK 212.1k
Elizabeth O'Farrell	Independent Director	less than a year	no data	no data

5.3yrs

Average Tenure

62yo

Average Age

Experienced Board: GE9's board of directors are considered experienced (5.3 years average tenure).

Genmab Management

Management criteria checks 4/4

Key information

Recent management updates

Genmab A/S Announces Executive Changes

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

High number of new directors

Recent updates

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Genmab A/S Revises Earnings Guidance for 2022

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Genmab A/S Provides Earnings Guidance for the Year 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Genmab A/S Announces Janssen Received Conditional European Marketing Authorization for RYBREVANT

High number of new directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age